UK company announcements filtered and explained for private investors.
Forterra PLC (FORT) · 2026-11-11
Forterra’s ten-month Group revenue was £282.7m, down 11.9% year on year on a like-for-like basis, and the Board now expects full-year adjusted EBITDA of approximately £50m, below company-compiled consensus of £54.8m. Lower sales volumes and weaker fixed-cost absorption are pressuring profitability.
Cavendish Financial PLC (CAV) · 2026-11-11
Cavendish Financial reported weaker interim results, with revenue falling to £22.948m and a £0.498m loss before tax in the six months ended 30 September 2026; the Board omitted the interim dividend, while management expects its pipeline to generate greater fee revenue over the next 12 months than in the reported period. The company is targeting more than £3m of annualised cost reductions over the next six months, although strategic hiring will offset part of the saving.
Cropper (James) PLC (CRPR) · 2026-11-11
James Cropper’s H1 FY27 results were ahead of the Board’s expectations, with revenue of £61.2m and Adjusted EBITDA of £7.8m, but FY27 year-end net debt is expected to be above the £2.7m H1 level, though below the £8.1m FY26 year-end level, as capex, ERP spending, tax and the interim dividend fall in H2. The reported H1 net debt figure benefited from period-end timing; normalised net debt was £5.5m.
Fuller Smith & Turner PLC (FSTA) · 2026-11-11
Fuller Smith & Turner said it now expects FY2027 adjusted profit before tax to be ahead of current market expectations after H1 adjusted PBT rose to £28.2m from £22.5m, although net debt excluding lease liabilities is expected to reach about £190m-£195m by year end.
ITV’s nine-month total advertising revenue fell 1% and was slightly below previous guidance; it expects Q4 advertising revenue to fall around 5%-10% year on year and full-year revenue to fall around 2%-3%. Digital revenue rose 7% to £461m and streaming hours increased 29%, partly offsetting weaker linear advertising.
ICG PLC grew H1 FY27 APM fee-related earnings 18% to £198.6m, but APM profit before tax fell to £287.3m from £351.6m; it reiterated its target to raise at least $55bn between 1 April 2024 and 31 March 2028, with $48bn raised since 1 April 2024. APM group operating cash flow fell to £219m from £467m, while net debt reduced to £93m; performance fee income fell against an H1 FY26 comparator that included a £72m one-off accounting-transition impact.
Ten Technologies Group PLC (TENG) · 2026-11-11
Ten Technologies Group said post-year-end trading is in line with current market expectations for 2027, with higher Net Revenue and improved profitability expected versus the prior period, after 2026 Net Revenue rose 6.1% to £69.7m and adjusted EBITDA increased 10% to £16.1m. Americas Net Revenue fell 0.4% to £24.3m as it lost a Medium contract and activity fell at two Extra Large contracts ahead of further digital rollout.
Spirax Group PLC (SPX) · 2026-11-11
Spirax Group’s ten-month organic sales growth and adjusted operating profit margin were in line with expectations and ahead of the first half, while it reiterated full-year targets for mid-single-digit organic revenue growth, margin above 2025’s 20.0% and cash conversion of around 90%. Net borrowings excluding leases fell to £541.6m at 31 October from £618.2m at 30 June, reducing its net debt-to-EBITDA ratio to 1.3x from 1.6x.
Castings PLC (CGS) · 2026-11-11
Castings PLC’s first-half profit before tax fell to £2.017 million from £4.975 million after a two-month power restriction at William Lee, but management expects the FY27 full-year result to be in line with recently revised market expectations, with company-compiled consensus for £9.0 million adjusted profit before tax. Foundry segment profit fell to £0.247 million from £3.975 million, while customer arrears from the disruption are expected to clear in the second half.
Motorpoint Group PLC (MOTR) · 2026-11-11
Motorpoint Group PLC lifted H1 FY27 profit before tax to £6.5m from £3.6m and kept FY27 expectations unchanged from September’s upgrade to market consensus. Net debt excluding leases rose to £14.3m at 30 September 2026 from £8.8m at 31 March 2026.
Taylor Wimpey PLC (TW.) · 2026-11-11
Taylor Wimpey expects full-year 2026 Group adjusted operating profit around the bottom of the £262m–£299m consensus range as subdued autumn trading cut UK net private sales rates excluding bulk deals to 0.54 per outlet per week, from 0.61. Its order book excluding joint ventures fell to about £1.984bn from £2.116bn, while year-end net cash is still expected to be about £250m, subject to land-purchase timing.
Pantheon Resources PLC (PANR) · 2026-11-11
Pantheon Resources has suspended trading while it pursues a proposed £5.0m gross fundraise at 7p per new share, which it says could fund working capital until approximately early June 2027. Farm-in negotiations remain uncertain, although the company has identified a target area for an up-dip Kodiak appraisal well.
Solid State PLC (SOLI) · 2026-11-11
Solid State has secured a US$26.2 million follow-on Project CAIN defence order, which management says further underpins existing FY26/27 and FY27/28 guidance. Delivery is expected in the first half of 2027.
Newmark Security PLC (NWT) · 2026-11-11
Newmark Security’s core HCM business traded in line with Board expectations in H1 2027, but revenue is expected to be weighted to the second half. Unaudited HCM revenue rose 5% to £8.3 million from £7.9 million in H1 2026.
Conduit Holdings Ltd (CRE) · 2026-11-11
Conduit Holdings reported nine-month gross premiums written down 3.8% to $999.9 million, while reinsurance revenue rose 1.6% to $673.2 million; management expects further rate softening, particularly in Property and Specialty, but rising market yields and reinvestment rates to support increasing investment income as cashflow is invested. Managed investments and cash rose 14% year on year to $2.3 billion, but the investment portfolio returned negative 0.4% as higher Treasury yields caused unrealised losses.
ATOME PLC faces an unresolved power-purchase agreement impasse that puts financing for its envisaged US$665m Villeta project at risk, although ANDE’s reappointed president may reopen dialogue. ATOME has notified termination of the 2022 PPA effective at the end of 2026 after negotiations failed.
Celebrus Technologies PLC (CLBS) · 2026-11-11
Celebrus Technologies plc has launched a buyback of up to 3.0m shares, worth about $2.0m at the 10 November price, but the shares are intended for treasury to meet future share-scheme obligations. Assuming full implementation and no further dealings by Mission Trail since 30 September 2026, its interest could rise to a maximum of 32.60%.
SEEEN’s GTChannel has secured $700,000 of two-year financing, repayable at $860,000 and secured against CSP revenues; the initial reseller contribution is expected to deliver at least 10% GTC revenue growth in 2027 over expected 2026 levels, and the combined arrangement to be earnings enhancing in 2027. The commercial upside depends on Breeze introducing creator channels and meeting revenue targets.
Eco Animal Health Group PLC (EAH) · 2026-11-11
Eco Animal Health has submitted ECOVAXXIN® MG for EU marketing authorisation, advancing a second proprietary vaccine but leaving approval and launch subject to EMA review. ECO says its regulatory plan remains in line with expectations and will continue work towards US authorisation.
BATM Advanced Communications Ltd (BVC) · 2026-11-11
BATM Advanced Communications has received an additional $4.0m order from a long-standing customer for its quantum-era-ready cybersecurity platform, extending their existing hardware-solution agreement. Delivery is expected during 2027.
Agronomics Ltd (ANIC) · 2026-11-11
Agronomics Ltd reported regulatory and commercial progress at two of its larger holdings: Formo received an FDA “no questions” letter for Enhanced Casein, a position carried at about 6.7% of NAV, while Clean Food Group launched CLEANOil™ in skincare, with a carrying value of about 5.0% of NAV. The Formo letter covers specified cheese analog uses and is not product approval.
RWS Holdings PLC (RWS) · 2026-11-11
RWS Holdings has launched Weava, a content-transformation platform that is available now.
Novacyt SA (NCYT) · 2026-11-11
Southern Cross Diagnostics, Novacyt’s Australian sponsor, has TGA approval to market and supply the Yourgene® Insight DPYD assay for approved clinical diagnostic use in Australia, moving beyond research-use-only sales. Novacyt estimates the Australian addressable market at about 16,000–66,000 tests a year, with annual reimbursed testing value to laboratories of about A$3.0m–A$12.0m at current Medicare reimbursement of about A$182 per test.
Gelion PLC (GELN) · 2026-11-11
Gelion PLC’s Australian subsidiary has gained AUKUS Authorised User status, which could ease eligible defence-market collaboration across Australia, the UK and US. Each transfer still requires classification, eligibility, end-user, location and pre-notification checks.
YouGov PLC published a direct validation study of its AI E-twins, reporting 90% within-one-point accuracy after adding ratings data, up from 78% using profiling data alone; the study did not measure the repeatability ceiling.
Quadrise PLC (QED) · 2026-11-11
Quadrise PLC’s exclusive global agreement with Nouryon expired on 31 October 2026 and will not be extended or replaced until Quadrise confirms its project and volume requirements. Nouryon will still support trials through individual orders, while Quadrise broadens its additive supply base.
Manx Financial Group PLC (MFX) · 2026-11-11
Manx Financial Group PLC’s Payment Assist has signed an agreement to put its Buy Now, Pay Later products into Spense’s platform for UK franchised dealerships, with Spense set to launch in the UK in 2027.
Acg Metals Ltd (ACG) · 2026-11-11
ACG Metals has started a refinancing process for its US$200 million senior secured bond by appointing managers for investor meetings ahead of a possible new senior secured bond issue, subject to market conditions.
East Star Resources PLC (EST) · 2026-11-11
East Star Resources PLC has advanced drilling at both copper joint ventures, while Xinhai has completed its A$1.5 million Stage 1 commitment and received an initial 15% interest in Verkhuba Ltd. Verkhuba’s programme is fully funded by the joint venture at no cost to East Star, which says it is carried to production for an expected 30% mine interest.
Thalia Therapeutics plc (THAT) · 2026-11-11
Thalia Therapeutics completed Lipisiran’s in vitro study, meeting the objectives needed to start in vivo work, but efficacy and durability remain to be established before later investment and development decisions.
Jangada Mines PLC (JAN) · 2026-11-11
Jangada Mines completed geophysics at its Molly Gold Project, identifying 15 targets including nine priorities, while a fully funded 11-hole, approximately 1,400-metre drilling programme is under way. Three holes are complete and assays are pending; the anomalies do not detect gold directly and require drilling confirmation.
Gunsynd PLC (GUN) · 2026-11-11
Gunsynd PLC has expanded the Barb Gold Project at nominal cost by staking a 256-hectare claim, taking the land package to about 6,946 hectares across 38 claims. All claims have been transferred to its wholly owned Canadian subsidiary, 1572340 B.C. Ltd.
Nativo Resources PLC (NTVO) · 2026-11-11
Nativo Resources has secured exclusive rights to evaluate a potential tailings-processing partnership in southern Peru, but the largely non-binding proposal requires technical and commercial approval, permitting, financing and definitive agreements.
Anglesey Mining PLC (AYM) · 2026-11-11
Anglesey Mining plans to use its recent £1.25 million fundraising to support the Parys Mountain development roadmap through to Q3 2028, with H1 2027 drilling expected to support an updated Mineral Resource Estimate.
Rift Helium PLC (RIFT) · 2026-11-11
Rift Helium has started the expanded 3D seismic survey at Upepo in line with guidance, but it cannot confirm a commercial helium accumulation and drilling is still needed.
Fulcrum Metals PLC (FMET) · 2026-11-11
Fulcrum Metals reported preliminary extraction of strontium, rubidium and scandium from Teck-Hughes tailings, broadening the potential application of its pilot platform. The results are not yet evidence of saleable products or commercial economics, with independent assays, repeat tests and downstream recovery work still required.
Guardian Metal Resources PLC (GMET) · 2026-11-11
Guardian Metal Resources PLC has approved in principle a spin-out of its Nevada non-tungsten exploration assets into Spin-Co, aiming for AIM admission by Q2 2027, but no binding agreements exist and completion is uncertain. Shareholders would keep indirect exposure through Guardian’s expected Spin-Co stake rather than receive Spin-Co shares directly. The update also reiterates CEO Oliver Friesen’s 181,817-share EMI option at 10.75p, the extension of his original options to 3 May 2031 and a capped tax indemnity after the original options did not qualify for the intended EMI treatment.
Orcadian Energy PLC (ORCA) · 2026-11-11
Orcadian expects its P2650 licence interest to increase from 50% to 100% after Triangle UK failed to pay a cash call and its parent entered administration, subject to Triangle UK’s withdrawal, NSTA approval and its co-operation.
Nuformix PLC (NFX) · 2026-11-11
Nuformix PLC has proposed a share-for-share acquisition of Biovara, but the largely non-binding deal has no agreed combined valuation and may require a move from the Main Market to AIM.
Somero Enterprises Inc (SOM) · 2026-11-11
Somero Enterprises’ proposed board-class amendment remains unresolved after the special meeting was adjourned because the required two-thirds support of outstanding shares was not reached. More than 65% of shares had voted and over 99% of votes cast supported the resolution.
Hydrogen Utopia International PLC (HUI) · 2026-11-11
Hydrogen Utopia International PLC said its share price fell significantly on 10 November 2026, and the Board could not identify a reason for the move.
Eco Animal Health Group PLC (EAH) · 2026-11-11
Eco Animal Health Group presents a risk-adjusted enterprise valuation of about £100 million for ECOVAXXIN MS and its R&D portfolio, but PRRSvmAb remains at proof-of-concept with an indicative £0 million–£100 million range conditional on a key near-term trial.
Verici Dx PLC (VRCI) · 2026-11-11
Verici Dx says its recent fundraise is expected to fund the business through cash-flow breakeven by the end of 2027. It will present at Mello2026 in London on 17 November, but says no new information will be disclosed.